Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 5—May 2007
Dispatch

Tuberculosis Drug Resistance and HIV Infection, the Netherlands

Catharina Hendrika Haar*†, Frank G.J. Cobelens*‡Comments to Author , Nico A. Kalisvaart*, Jan J. van der Have†, Paul J.H.J. van Gerven*, and Dick van Soolingen§
Author affiliations: *KNCV Tuberculosis Foundation, The Hague, the Netherlands; †Municipal Health Service, Groningen, the Netherlands; ‡Academic Medial Centre, Amsterdam, the Netherlands; §National Institute of Public Health and the Environment, Bilthoven, the Netherlands;

Main Article

Table 2

Prevalence of secondary drug resistance among previously treated tuberculosis patients, the Netherlands, 1993–2001*


No. HIV negative (%) 
(n = 294)
No. HIV positive (%)
(n = 21)
Fully susceptible 232 (78.9) 15 (71.4)
Resistant to 1 drug:
  Isoniazid
  Rifampin
  Streptomycin
34 (11.9)
20 (6.8)
0
14 (4.8)
4 (19.0)
2 (9.5)
2 (9.5)
0
Resistant to 2 drugs
17 (5.8)
0
Resistant to 3 drugs
4 (1.4)
0
Resistant to 4 drugs
7 (2.4)
2 (9.5)
Any resistance
62 (21.1)
6 (28.6)
Any resistance to:


  Isoniazid
48 (16.3)
4 (19.0)
  Rifampin
15 (5.1)
4 (19.0)*
  Streptomycin
36 (12.2)
2 (9.5)
  Ethambutol
9 (3.1)
2 (9.5)
Multidrug resistance† 15 (5.1) 2 (9.5)

*Undajusted odds ratio 4.12 (95% confidence interval 1.01–15.67, p = 0.036).
†Resistant to at least isoniazid and rifampin.

Main Article

Page created: June 23, 2010
Page updated: June 23, 2010
Page reviewed: June 23, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external